{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-34.1","upperLimit":"-2.3","value":"-27.8"},{"groupId":"OG001","lowerLimit":"-51.8","upperLimit":"-16.4","value":"-36.7"},{"groupId":"OG002","lowerLimit":"-4.9","upperLimit":"19.6","value":"2.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"P-Trap5b, change from baseline at 48 weeks.","dispersionType":"Inter-Quartile Range","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.","reportingStatus":"POSTED","timeFrame":"Change from baseline at 48 weeks reported.","title":"Percent Change From Baseline in p-Tartrate-resistant Acid Phosphatase 5b (Trap5b).","type":"SECONDARY","unitOfMeasure":"% change"}